CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
  
  LEARNING OBJECTIVES

  • Individualize the selection and sequencing of systemic therapy for patients with newly diagnosed or relapsed/refractory (R/R) CLL, considering clinical presentation, age, performance status (PS), biomarker profile and coexisting medical conditions.
  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for diffuse large B-cell lymphoma (DLBCL) in order to determine the current and potential utility of those agents in clinical practice.
  • Consider patient age, PS and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients about the potential benefits of this strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for CLL, FL, MCL and DLBCL and thus support quality of life and continuation of treatment.
  • Recall new data with agents and strategies currently under investigation for CLL and various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and short post-test, enables the participant to earn up 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCO22AMLMDS/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Ian W Flinn, MD, PhD
  Director of Lymphoma Research Program
  Sarah Cannon Research Institute
  Tennessee Oncology
  Nashville, Tennessee
  
  Consulting Agreements (to Sarah Cannon Research Institute): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Century Therapeutics, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Great Point Partners LLC, Hutchison MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Unum Therapeutics, Verastem Inc, Vincerx Pharma, YL-Pharma Co Ltd; Research Grants (to Sarah Cannon Research Institute): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research and Development Corporation, Unum Therapeutics, Verastem Inc.
  
  Brian T Hill, MD, PhD
  Director, Lymphoid Malignancy Program
  Cleveland Clinic Taussig Cancer Institute
  Cleveland, Ohio
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Epizyme Inc, Genentech, a member of the Roche Group, Kite, A Gilead Company, MorphoSys, Novartis; Contracted Research: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Kite, A Gilead Company, MorphoSys, Novartis.
  
  John P Leonard, MD
  Richard T Silver Distinguished Professor of Hematology and Medical Oncology
  Senior Associate Dean for Innovation and Initiatives
  Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
  Weill Cornell Medicine
  New York, New York
  
  Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Grail Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Lilly, Merck, Mustang Bio, Pfizer Inc, Roche Laboratories Inc, Second Genome, Sutro Biopharma; Contracted Research: Epizyme Inc, Genentech Foundation, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group.
  
  Matthew Lunning, DO
  Associate Professor
  Fred and Pamela Buffett Cancer Center
  Associate Vice Chair of Research, Department of Medicine
  Assistant Vice Chancellor of Clinical Research
  University of Nebraska Medical Center
  Omaha, Nebraska
  
  Consulting Agreements: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, EUSA Pharma, Fate Therapeutics, Genentech, a member of the Roche Group, Instil Bio, Kite, A Gilead Company, Kyowa Kirin Co Ltd, Legend Biotech, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics Inc, Sana Biotechnology, TG Therapeutics Inc.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Clinical Professor of Medicine
  Division of Medical Oncology
  University of British Columbia
  Associate Editor, Blood
  Vancouver, British Columbia, Canada
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Genentech, a member of the Roche Group, Teva Oncology.
  
  Mitchell R Smith, MD, PhD
  Clinical Professor of Medicine
  George Washington University
  Washington, DC
  
  Advisory Committee: Janssen Biotech Inc; Speakers Bureau: Acrotech Biopharma.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Kite, A Gilead Company, and Lilly.
  
  Release date: June 2022
  Expiration date: June 2023
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.